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Abstract: Lipids are one of the primary metabolites of microalgae and cyanobacteria, which enrich
their utility in the pharmaceutical, feed, cosmetic, and chemistry sectors. This work describes
the isolation, structural elucidation, and the antibiotic and antibiofilm activities of diverse lipids
produced by different microalgae and cyanobacteria strains from two European collections (ACOI
and LEGE-CC). Three microalgae strains and one cyanobacteria strain were selected for their
antibacterial and/or antibiofilm activity after the screening of about 600 strains carried out un-
der the NoMorFilm European project. The total organic extracts were firstly fractionated using
solid phase extraction methods, and the minimum inhibitory concentration and minimal biofilm
inhibitory concentration against an array of human pathogens were determined. The isolation
was carried out by bioassay-guided HPLC-DAD purification, and the structure of the isolated
molecules responsible for the observed activities was determined by HPLC-HRESIMS and NMR
methods. Sulfoquinovosyldiacylglycerol, monogalactosylmonoacylglycerol, sulfoquinovosyl-
monoacylglycerol, α-linolenic acid, hexadeca-4,7,10,13-tetraenoic acid (HDTA), palmitoleic acid,
and lysophosphatidylcholine were found among the different active sub-fractions selected. In
conclusion, cyanobacteria and microalgae produce a great variety of lipids with antibiotic and
antibiofilm activity against the most important pathogens causing severe infections in humans.
The use of these lipids in clinical treatments alone or in combination with antibiotics may provide
an alternative to the current treatments.
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1. Introduction
Nowadays, antimicrobial resistance (AMR) is one of the major public health challenges.
The alarming decline in the effectiveness of antibiotic treatments due to the increasing
resistance acquired by pathogens has put the world in a global AMR crisis [1,2]. In addi-
tion, biofilm formation makes these bacteria up to 1,000-fold more resistant to antibiotics.
Therefore, there is an urgent need to find new compounds to solve this problem, and one
of the neglected ecological niches to look for new bioactive compounds against pathogen
bacteria is the ocean, which covers approximately 71% of Earth’s surface. Indeed, aquatic
environments are some of the most promising places for the discovery of new antibiotics
and antibiofilm compounds due to their extraordinary biodiversity, from microscopic to
macroscopic organisms.
Microalgae (photosynthetic eukaryotes) and cyanobacteria (photosynthetic prokary-
otes) represent a large part of the biodiversity of these aquatic environments as they are
at the base of their food chain [3,4]. These microorganisms can adapt to many environ-
ments, including extreme ones characterized by the presence of toxic substances or extreme
temperature, values of pH, or salinity. This feature enables the development of different
defense mechanisms and production of bioactive compounds that allow them to survive in
such extreme conditions [2,4–6]. The chemical diversity of these metabolites, combined
with their activity inhibiting multiple tolerant pathogens’ growth [3], place these microor-
ganisms at the forefront of drug discovery (the process associated with the screening and
discovery of bioactive molecules and their subsequent development as pharmaceuticals)
and antimicrobial resistance research.
Therefore, although drug development can be challenging, new drugs can be devel-
oped from secondary metabolites of microalgae and cyanobacteria, such as dolastatin,
the only currently approved drug derived from cyanobacteria (Symploca hydnoides and
Moorea producens, formerly Lyngbya majuscula) [7–9]. The antibiotic activity of microalgae
and cyanobacteria has been attributed to compounds belonging to several chemical classes,
such as alkaloids, aromatic compounds, acetogenins, cyclophanes and paracyclophanes,
dicarboximides, indanes, indoles, lactones, lipids, macrolides, phenols, phlorotannins,
peptides, pigments, polyphenyl ethers, polysaccharides, porphinoids, sterols, and ter-
penes [1–7,9]. Considering all this chemical diversity, this work will focus on antimicrobial
lipids, which can generally be defined as lipid amphiphiles that interact with and desta-
bilize bacterial cell membranes, and they are attractive candidates for exploration as new
broad spectrum antibacterial agents to fight against bacterial infections [10–12]. They can
be classified into three broad categories: fatty acids (hydrocarbon chains with a carboxylic
acid functional group), glycoglycerolipids (composed of glycerol, fatty acids, and carbohy-
drates), and monoglycerides (esterified adducts of a fatty acid and glycerol molecule) [11].
Fatty acids are ubiquitous in nature and can be defined as organic compounds with
carboxylic acids and long aliphatic chains that can be straight or branched, as well as
saturated, unsaturated, or hydroxylated. Their multiple biological properties, including
antibiotic properties, are well-known [13–15]. In fact, the antibacterial effects of fatty acids
were first described in the 1880s by Dr. Robert Koch and colleagues who observed that fatty
acids inhibited the growth of Bacillus anthracis. However, these compounds lost importance
due to the golden age of antibiotics, but they have now regained prominence with the
growing impact of antibiotic-resistant bacteria [10].
The potent antibacterial effect described for fatty acids led to studies focused on the
use of omega-3 polyunsaturated fatty acids, such as docosahexaenoic acid (DHA) and eicos-
apentaenoic acid (EPA), as antibacterial and antibiofilm agents against periprosthetic joint
infections caused by multi-drug resistant strains (Staphylococcus epidermidis, S. aureus, and
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coagulase-negative Staphylococci) [16,17]. In addition, EPA and DHA have been reported
as having the ability to bind to non-specific proteins, and this non-specific mechanism
of action is very beneficial in reducing antibiotic resistance [17]. These studies provide
increasing evidence for the use of fatty acids as an alternative to classical antibiotics, or in
combination with them, to enhance their effects [18].
The multiple mechanisms that confer fatty acids their antibacterial activity are not
yet fully understood, although it is known that these compounds are released to the
environment when the cell loses its integrity, and they act as a defense mechanism to
protect bacterial populations from grazing predators or pathogenic bacteria [19]. It seems
that bacterial cell membranes could be the principal target of polyunsaturated fatty acids
(such as DHA or EPA) or saturated fatty acids (such as lauric acid) through the insertion
of their long carbon chains, thereby causing cell leakage, reducing nutrient intake, and
affecting cellular respiration [12,19–23].
As a general rule, cyanobacteria and microalgae contain high amounts of proteins,
with values even higher than soybean, corn, and wheat. Of particular interest is also their
content of polyunsaturated fatty acids, including α-linolenic acid (ALA), γ-linolenic acid
(GLA), EPA, DHA, and arachidonic acid (ARA). Although lipid accumulation is extremely
dependent on the culture conditions, the lipid content of some microalgae species, such
as Nannochloropsis oceanica, Chlorella vulgaris, or Scenedesmus obliquus, can represent more
than 20% of their dry weight [24]. The first compound with antibiotic activity isolated from
microalgae was described by Pratt et al. in 1944, and it was purified from chloroform and
benzene extracts of Chlorella vulgaris as a mixture of fatty acids. It was named chlorellin
and was able to inhibit the growth of both Gram-positive (Bacillus subtilis, Staphylococcus
aureus, and S. epidermidis) and Gram-negative (Escherichia coli and Pseudomonas aeruginosa)
bacteria [25,26]. Since then, the interest in microalgae as potential antibiotic producers has
led to several large screening programs to investigate the potential of different freshwater
and marine taxonomic groups of microalgae to inhibit the growth of pathogenic and
foodborne bacteria [27–31]. Some of the antibacterial compounds present in the extracts
were characterized and, in most cases, these were free fatty acids. Short chain fatty acids
from Haematococcus pluvialis [32] and long chain fatty acids from Scenedesmus obliquus [33]
have been shown to exhibit antibacterial activity against S. aureus and E. coli. On the other
hand, it was found that polyunsaturated fatty acids from Chlorococcum strains HS-101
and Dunaliella primolecta were active against methicillin-resistant S. aureus (MRSA) [34].
It has also been described that polyunsaturated fatty acid (EPA), monounsaturated fatty
acid (palmitoleic acid, PA), and polyunsaturated fatty acid (hexadecatrienoic acid, HTA)
from the diatom Phaeodactylum tricornutum are active against MRSA [35,36]. Finally, the
antibiotic activity of supercritical CO2 extracts from the microalga Chaetoceros muelleri has
been related to the lipid composition [37].
Glycoglycerolipids (GLs) represent a neglected class of metabolites of increasing inter-
est. Nevertheless, their low natural abundance coupled with their difficult isolation makes
it hard to evaluate their bioactivities, which include antibacterial, antiviral, anti-tumor, and
anti-inflammatory activities [38]. These compounds are especially abundant in microalgae,
macroalgae (macroscopic algae), and cyanobacteria and exhibit a glycerol backbone that
anchors one or two acyl chains esterified at the sn-1 and sn-2 positions, and a sugar group
attached at the sn-3 position in a β-anomeric linkage [39]. GLs can be classified into three
broad classes according to the nature of the glycosidic head: monogalatosyldiacylglycerols
(MGDGs), digalactosyldiacylglycerols (DGDGs) (and their monoacylated forms, mono-
galactosylmonoacylglycerols (MGMGs), and digalactosylmonoacylglycerols (DGMGs)),
and sulfoquinovosyldiacylglycerols (SQDGs) (and their monoacylated form sulfoquinovo-
sylmonoacylglycerols, SQMG) [39]. The former two are neutral glycolipids, and the latter
are anionic sulfolipids [40]. The biological activities of GLs are known to be dependent on
sugar moiety and acyl chains; however, the specific structure-activity relationship is not
yet fully understood [38].
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GLs are mainly located in the plastid and thylakoid membranes of the chloroplasts of
eukaryotic algae and perform important functions related to the fluidity and stabilization
of photosynthetic apparatus membranes, as well as photoprotection mechanisms involv-
ing the xanthophyll cycle. The membrane composition of chloroplasts (and, therefore,
cyanobacteria) is highly conserved, with MGDG and DGDG being the most abundant
lipids [41,42]. They are not only interesting because of their powerful surfactant and emul-
sifying properties but also because they are biodegradable and environmentally non-toxic.
In fact, because they are odorless, tasteless, and non-irritants, they have interesting applica-
tions in the food industry and in cosmetic formulations [43].
Finally, another important class of lipids is phospholipids. They are the component
of all cell membranes and are synthesized by both prokaryotic and eukaryotic organisms,
playing important structural and metabolic roles in these cells. Most are characterized
by a common backbone of phosphatidic acid (PA), formed from L-glycerol 3-phosphate
with two fatty acids esterified on positions one and two. The algae contain three major
phospholipids: phosphatidylglycerol (PG), phosphatidylethanolamine (PE), and phos-
phatidylcholine (PC), which show diverse biological antitumoral, antiviral, and antibac-
terial activities [44]. Among these, lysophosphatidylcholine (LPC) is a chemotactic factor
that stimulates immune cells and regulates the balance between the release of pro- and
anti-inflammatory cytokines. It has been reported that the pretreatment of bacterial in-
fections with LPC showed beneficial effects, preventing the release of proinflammatory
cytokines and increasing the release of anti-inflammatory cytokines, and, therefore, helping
to eradicate the infection [45].
In this work, the isolation and structural elucidation, as well as the antibiotic and
antibiofilm activities, of diverse lipids produced by different microalgae and cyanobac-
teria strains were studied. These molecules can be used for coating prosthetic devices
to avoid bacterial adhesion and posterior biofilm-related infection, or as new antibiotics
or adjuvants.
2. Results
2.1. Microalgae and Cyanobacteria Strains Selection
The microalgae and cyanobacteria strains from the Coimbra Collection of Algae
(ACOI) and the Blue Biotechnology and Ecotoxicology Culture Collection (LEGE-CC) col-
lections were selected among 600 strains after the screening of the antibiotic and antibiofilm
activities of total cellular extracts in the NoMorFilm H2020 project. The extracts were ob-
tained from freeze-dried biomasses sequentially extracted with hexane, ethyl acetate, and
methanol [8]. These strains belonged to the phyla Cercozoa, Charophyta, Chlorophyta, Crypto-
phyta, Cyanobacteria, Euglenophyta, Glaucophyta, Haptophyta, Miozoa, Ochrophyta, Rhodophyta,
and two unknown species [8]. The antibiofilm and antibacterial activities of these extracts
were analyzed against S. aureus, S. epidermidis, K. pneumoniae, E. cloacae, P. aeruginosa, E. coli,
C. parapsilosis, C. albicans, and Coagulase-negative Sthaphylococcus (CoNS) strains, and those
showing both activities were further studied.
2.2. Antibiotic Activity of Fractions and Sub-fractions
Among the different solid phase extraction (SPE) fractions and high-performance liquid
chromatography with diode-array detection (HPLC-DAD) sub-fractions assayed, only eight
of them showed an antibiotic effect against the bacterial pathogen S. aureus (Table 1). No
activity was found against the other eight bacterial species included in the study.
2.3. Antibiofilm Activity of Fractions and Sub-Fractions
Among the extracts assayed, those from the methanol (C) and ethyl acetate (B) ex-
traction were the most active against the microorganisms under study. The sub-fraction
showing the antibiofilm activity of each strain presented a biofilm inhibition of 60% for
CoNS, E. coli, and C. albicans in the case of ACOI 118_C8_F48-F49; 80% of inhibition for
CoNS and E. coli in the case of ACOI 1261_C8_F26-F27 and F47-F51, respectively; and
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61% and 70% of biofilm inhibition in CoNS in the case of the sub-fractions F34 and F48 of
Sphaerospermopsis sp. LEGE00249, respectively (Table 2).
Table 1. Antibiotic activity.
Microalgae/Cyanobacteria
Strain SPE-Fraction HPLC Sub-Fraction Molecules Detected Microorganism
ACOI 1261 B8 F52 C16:0 MGMG,C18:0/C16:0 SQDG S. aureus
ACOI 118 C6 F39 C16:0 SQMG S. aureus
ACOI 565
C8 F67 ALA S. aureus
C4 F68 HDTA S. aureus
LEGE 00249
- F34 (from Group AF69-F76 refractionation) C16:1 MGMG S. aureus
- F48 (from Group AF69-F76 refractionation) C16:0 MGMG S. aureus
- F83 ALA, C16:0/C18:0 SQDG S. aureus
- F86 POA S. aureus
SPE, solid phase extraction; HPLC-DAD, high-performance liquid chromatography with diode-array detection; SQDG, sulfoquinovosyl–
diacylglycerol; MGMG, monogalactosyl–monoacylglycerol; SQMG, sulfoquinovosyl–monoacylglycerol; ALA, α-linolenic acid; HDTA,
hexadeca-4,7,10,13-tetraenoic acid; POA, palmitoleic acid; B, ethyl acetate fraction; C, methanol fraction; F, sub-fraction.
Table 2. Antibiofilm activity.
Microalgae/Cyanobacteria




F26-27 C16:0 MGMG,C18:0/C16:0 SQDG CoNS 80%















ACOI 118 C6 F36-38 C16:0 SQMG CoNS 34%














F34 (from Group A
F69-F76
refractionation)
C16:1 MGMG CoNS 61%
F48 (from Group A
F69-F76
refractionation)
C16:0 MGMG CoNS 70%
SPE, Solid Phase Extraction; HPLC-DAD, high-performance liquid chromatography with diode-array detection; SQDG, sulfoquinovosyldia-
cylglycerol; MGMG, monogalactosylmonoacylglycerol; DGMD, digalactosylmonoacylglycerol; SQMG, sulfoquinovosyl–monoacylglycerol;
LPC, lysophosphatidylcholine; B, ethyl acetate fraction; C, methanol fraction; F, sub-fraction.
2.4. HRESIMS and NMR Results
The structure of the compounds responsible for the antibiotic and antibiofilm activities was
elucidated based on the combination of spectroscopic and spectrometric methods (Figure 1).
The sulphoquinovosyl backbone in SQDG and SQMG was identified by 1H NMR
by the anomeric proton (δH 4.77 ppm, d J 3.7 Hz; δC 99.8 ppm) and the two diasterotopic
protons of the methylene group attached to the sulphonyl moiety. These protons resonate
at δH 2.93 ppm (dd J 14.4 Hz, 9.1 Hz) and 3.37 ppm and showed a correlation in the HSQC
spectrum with the carbon at δC 53.9 ppm. In the sample ACOI 1261_B8_F52, the sn-1 (δH
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4.51, 4.19 ppm/ δC 63.9 ppm) and sn-2 (δH 5.32 ppm/ δC 71.4 ppm) signals of the glycerol
in SQDG were unambiguously identified [46]. The lack of the characteristic signal of sn1
of glycerol in SQDG in ACOI 118_C6_F39 indicated that the glycerol moiety attached to
sulphoquinovose was partially hydrolyzed. The inspection of the HSQC spectrum and
comparison with the data from the literature evidenced the presence of SQMG hydrolyzed
at the sn-2 position of the glycerol [47]. In addition, the 1H NMR spectrum of the ACOI
1261_B8_F52 sub-fraction also showed the signal of the anomeric proton of β-galactosyl
residue (δH 4.237 ppm, d J 7.7 Hz; δC 105.3 ppm). Based on the correlations in the HSQC
spectrum and the comparison of the 1H and 13C chemical shifts with those reported in the
literature [46], this proton was assigned to MGMGs in which the acyl chain is attached
to the sn1 of the glycerol. The nature of the acyl chains attached to glycerol moiety in
these compounds could not be unambiguously determined by 1H NMR, but it was de-
duced through the HRESIMS analysis. The mass spectrum of ACOI 1261_B8_F52 displayed
peaks at m/z 821.5456 and 491.3227. The ion at m/z 821.5456 was consistent with a sulpho-
quinovosyldiacylglycerol bearing C18:0 and C16:0 acyl chains and C18:0/C16:0 SQDG
([M]−, calcd. for C43H81O12S−: 821.5454), whereas that at m/z 491.3227 was identified
as 1-palmitoyl-3-O-galactosyl-sn-gycerol, C16:0 MGMG, ([M − H]−, calcd. for C25H47O9:
491.3220). On the other hand, the mass peak at m/z 555.2842 for ACOI 118_C6_F39 allowed
1-palmitoyl-3-O-sulphoquinovosyl-sn-gycerol, C16:0 SQMG, to be identified ([M]−, calcd.
for C25H47O11S−: 555.2845) (Figure 2).
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MGMGs were also detected as the major compounds in LEGE 00249_F34 and LEGE
00249_F48. The analysis of the δ 3.0-0.5 ppm region in the 1H NMR spectra of these samples
indicated that MGMGs differ in the acyl chain, are monounsaturated in LEGE 00249_F34,
and aturated in LEGE 00249_F48. In fact, the HRESIMS data of LEGE 00249_F48 confirmed
the presence of C16:0 MGMG also found in ACOI 1261_B8_F52 (see above). The peak at
m/z 489.3070 ([M − H]−, calcd for C25H45O9: 489.3064) found in the mass spectrum of
LEGE 00249_F34 indicated the presence of a palmitoleyl moiety.
The existence of free fatty acids, such as α-linolenic acid (ALA, C18:3ω-3), hexadeca-
4,7,10,13-tetraenoic acid (HDTA, C16:4 ω-3), and palmitoleic acid (POA, C16:1 ω-7), in
some of the sub-fractions studied (Table 1) was established by HRESIMS through the ions
at m/z 277.2176 ([M − H]−, calcd. for C18H29O2: 277.2168), m/z 247.1704 (([M − H]−, calcd.
for C16H23O2,: 247.1698), and m/z 253.2176 ([M − H]−, c lcd. for C16H29O2: 253.2168),
respectively. These three free fatty acids were also unambiguously identified by 13C NMR
spectroscopy [48,49].
The analysis of the NMR spectra suggested a similar composition for the ACOI
565_C8_48 and ACOI 565_C8_49 samples. A detailed NMR study of ACOI 565_C8_49
provided the identification of the major compounds. Signals at δH 4.24 ppm (d J 7.0 Hz),
δC 105.3 ppm, nd δH 4.87 ppm (d J 3.8 Hz), δC 100.6 ppm were assigned to the anomeric
protons of the sugar moiety in sn-2 digalactosymonoacyl glycerols (DGMG) ) (1’ and 1”,
respectively, in Figure 3a) [50]. Furthermore, the 13C spectrum of this sub-fraction deter-
mined the esterification with palmitoyl acid (C16:0). In agreement with this, the HRESIMS
showed a major peak at m/z 653.3754 (([M − H]−, calcd for C31H57O14: 653.3748).
The presence of 1-stearoyl-sn-glycero-3-phosphocholine (C18:0 LPC) in this sub-
fraction was deduced from the HRESIMS spectrum showing a peak at m/z 522.3562
([M − H]−, calcd. for C26H53NO7P: 522.3560). A similar structure with a shorter aliphatic
chain, 1-palmitoyl-sn-glycero-3-phosphocholine (C16:0 LPC), was found to have the molecular
formula C24H50NO7P according to the HRESIMS spectrum showing a peak at m/z 494.3255
([M − H]− calcd. for C24H49NO7P: 494.3247). The 31P{1H} NMR spectrum consisted of two
signals at δP 0.29 and -0.42 ppm, which were assigned to lysophosphatidylinositol, 1-oleyl-
sn-glycero-3-phosphatylinositol (C18:1 LPI) according to the m/z 597.3046 ([M]−, calcd. for
C27H50O12P−: 597.3045), and lys p sophatidylcholine, respectively [51–53]. The lack of
correl tions in the 1H, 31P HMQC spectrum (Figure 3b) b tween the phosphorous signals
and protons resonances at ca. δH 5.25 ppm evidenced that the position sn-2 of the glycerol
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was not esterified. The HRESIMS spectrum also identified C16:0 SQMG in the mixture
(Table 2). However, the relative proportion of this compound was below the detection
level of 1H NMR spectroscopy. The NMR analysis of the ACOI 565_C8_49 subfraction also
identified monoacyl-N,N,N-trimethylhomoserine (MGTS). However, the nature of the acyl
chain could not be determined. The identification of MGTS (Figure 3a) was achieved by
the methyl resonance of the tetramethylammonium group at δH 3.21 ppm/δC 52.4 ppm,
the correlations found in the 2D spectra, and the lack of the resonances for the sn2 position
of the glycerol in DGTS at δH 5.26 ppm/δC 71.7 ppm [54] (Figure 3).
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Therefore, the elucidated compounds with antibacterial and antibiofilm activity
were (Figure 4):
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2.5. Antibiotic and Antibiofilm Activity of α-Linolenic Acid (ALA) and
1-Palmitoyl-sn-glycero-3-phosphocholine (C16:0 LPC)
As C16:0 LPC has not shown antibiotic activity, only the antibiotic activity of ALA was
tested against the three microorganisms used, E. coli, S. aureus, and C. parapsilosis. In these
experiments, thi polyunsaturated fatty acid was only active against the Gram-p itive
bacterium (S. aureus) and, to a lesser extent, against the yeast (C. parapsilosis) (Table 3).
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Table 3. Antibiotic activity of ALA.




MIC, minimum inhibitory concentration.
The antibiofilm activities of ALA and C16:0 LPC were tested against all the microor-
ganism strains used in the antibiofilm screening.
A species-dependent effect on biofilm inhibition was observed. Thus, the antibiofilm
activity in K. pneumoniae, E. coli, S. epidermidis, and C. parapsilosis is mainly due to the
presence of C16:0 LPC in a higher proportion or alone. On the contrary, the antibiofilm
activity in C. albicans is due to the presence of a higher proportion of ALA, and the
antibiofilm activity in S. aureus and P. aeruginosa is due to the presence of ALA alone and
when it is also mixed with C16:0 LPC but at lower concentrations (Table 4). The activities
are comparable with the minimum biofilm inhibitory concentrations (MBICs) obtained
with the corresponding extracts.
Table 4. Synergies of antibiofilm activity between C16:0 LPC and ALA.
50% Biofilm Inhibition
Microbial Strain ALA(mg/L)
ALA 1: C16:0 LPC 1
(mg/L)
ALA 1: C16:0 LPC 0.5
(mg/L)
ALA 0.5: C16:0 LPC 1
(mg/L) C16:0 LPC (mg/L)
K. pneumoniae >128 >128 >128 2 32
P. aeruginosa 32 64 32 16 >128
E. coli >128 >128 128 64 32
E. cloacae 128 128 128 128 128
CoNS 128 128 128 128 128
S. epidermidis 128 128 128 64 64
S. aureus 64 128 128 64 >128
C. parapsilosis 128 128 64 64 64
C. albicans 1 8 64 >128 128
ALA, α-linolenic acid; C16:0 LPC, 1-palmitoyl-sn-glycero-3-phosphocholine.
3. Discussion
Microalgae are organisms of great interest due to their ability to synthesize biologically
active compounds, their rapid growth, allowing a high availability of biomass, and the
possibility of adjusting their biochemical composition depending on the cultivation condi-
tions [55]. Thus, the use of microalgae, as well as cyanobacteria, has become increasingly
important for humans due to their potential antimicrobial properties, among others. The
compounds associated with these bioactivities are normally produced in small quantities
from microalgae because most of them are secondary metabolites. However, lipids are one
of the primary metabolites of microalgae and cyanobacteria, which enrich their utility in
the form of food, pharma, and fuels.
In this work, two strains of the chlorophyta Scenedesmus brasiliensis, ACOI 1261 and
ACOI 565, were studied for their production of antibiotic lipids and, specifically, in this
case, HDTA and ALA fatty acids (Table 1). The ability of the Scenedesmus genus to produce
antibiotic molecules of a lipid nature, similar to the antibiotic fatty acids identified in
this work, has been described previously; specifically, HDTA was also isolated from a
lipid extract of Scenedesmus obliquus rich in different fatty acids, such as palmitic, oleic,
or linolenic acids. The broad-spectrum antibiotic activities of HDTA have been reported,
although its major activity is focused on Gram-positive bacteria [56], as is the case in this
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work (S. aureus bactericidal activity). This polyunsaturated fatty acid is not exclusive to
microalgae [57] since it has also been identified in marine bacteria, such as Pseudoalteromonas
sp., showing an attenuating effect on Vibrio alginolyticus biofilms [58]. Similarly, the unusual
polyunsaturated fatty acid hexadeca-6,9,12-trienoic acid (structurally very similar to HDTA)
isolated from the diatom Phaeodactylum tricornutum was found to be active against Gram-
positive bacteria (S. aureus), as well as against the Gram-negative marine pathogen Listonella
anguillarum [35].
Two other microalgae species, Chlorella vulgaris and Scenedesmus obliquus, are rich
producers of ALA, with this polyunsaturated fatty acid representing up to 22% of the
total fatty acids content [26]. In addition, potent antimicrobial activities against a wide
range of Gram-positive bacteria, such as Listeria monocytogenes, B. cereus, and S. aureus,
have been attributed to this fatty acid [59–61], as well as against Gram-negative bacteria,
such as Helicobacter pylori [62]. Its inhibitory effect on fatty acid biosynthesis in S. aureus
is well-known [24] and may explain the bactericidal activity of this polyunsaturated fatty
acid found to be effective against this Gram-positive bacteria in this work (Tables 1 and 3).
ALA also presents moderate antifungal activity against C. parapsilosis, although to a lesser
extent than in the case of S. aureus (Table 3). On the other hand, it has been reported that
ALA was able to inhibit enzymes, such as bacterial enoyl–acyl carrier protein reductase
(FabI), necessary for fatty acid biosynthesis within the plasma membrane [12,19–21]. These
mechanisms of action may explain why Gram-positive bacteria are traditionally more sen-
sitive than Gram-negative bacteria (the MIC value of ALA in the case of E. coli was higher
than 250 mg/L, Table 3), which possess an outer membrane, making the penetration and
bactericidal effect of these compounds more difficult [12,26,41]. In this work, the antibiotic
fatty acid ALA was also identified and isolated from the cyanobacterium Sphaeropermopsis
sp. LEGE 00249 (Table 1).
Another unsaturated fatty acid, POA, is known to be the main antimicrobial fatty
acid that protects against S. aureus causing skin infections in mammals [63]. Fatty acids-
based microemulsions based on POA were able to inhibit the growth of S. aureus [64],
and this fatty acid has shown to have a potent antibacterial effect against Streptococcus
sp. and Neisseria gonorrhoeae [65,66]. POA from the diatom Phaeodactylum tricornutum
was active against MRSA [37,38]. Recently, it has been shown that POA was able to alter
the Acinetobacter baumannii quorum sensing (QS) communication system by decreasing
the QS regulator AbaR, which decreased biofilm formation by up to 38% [67]. Extracts
of the cyanobacterium Synechocystis sp. rich in POA were active against S. aureus [68].
In this work, POA was also identified and isolated from another cyanobacteria strain,
Sphaerospermopsis sp. LEGE 00249. POA is a poor substrate for phospholipid biosynthesis
and consequently accumulates in the cell, with a deleterious effect on metabolism [69]. The
results presented are in line with those of previous studies, showing antibacterial activity
against S. aureus.
As far as GLs are concerned, several studies have identified fractions of these com-
pounds from algae with antimicrobial activity, but it was only possible to isolate and
characterize the main compounds responsible for this activity in some cases. A crude
extract of seaweed Fucus evanescens rich in glycolipids showed strong antibacterial activity
against Hemophilus influenza, Legionella pneumophila, Cutibacterium acnes, and Streptococ-
cus pyogenes, as well as against Clostridium difficile and S. aureus. The authors chemically
synthesized this major glycolipid (MGDG), but the effect was reduced with respect to
the glycolipid-rich fraction, suggesting a possible synergistic effect [70]. On the other
hand, three sub-fractions from an organic extract of Sargassum vulgare rich in MGDG,
DGDG, and SQDG showed inhibitory activity against biofilm-forming marine bacteria
Pseudoalteromonas elyakovii, Halomonas marina, and Shewanella putrefaciens at MBIC values
of 0.01 µg/mL [71]. MGDG-palmitoyl purified from a methanolic extract of the cyanobac-
terium Oscillatoria acuminata was more effectively active against extended-spectrum beta-
lactamase (ESBL)-producing bacteria (E. coli, Stenotrophomonas maltophilia, and Enterobacter
asburiae) than fourth-generation cephalosporins. In addition, confocal laser scanning mi-
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croscopy studies showed that the cell membrane was damaged, leading to cell lysis [72]. In
this work, the cell extract from another cyanobacterium, Sphaerospermopsis sp. LEGE 00249,
as well as extracts from the microalgae S. brasiliensis ACOI 1261, gave rise to fractions
enriched in MGMGs, also showing antibacterial activity against S. aureus (Table 1). More-
over, a glycolipid-rich fraction, the main bioactive lipid of which was MGDG (20:5/16:0),
isolated from the red alga Chondria armata, showed antibiotic activity against C. albicans,
C. neoformans, and Klebsiella sp [73].
While in this work no antifungal activity associated with fractions enriched in MGDGs
(Table 1) was observed, the structurally similar GLs, SQDG, and SQMG, isolated from the
macroalgae Ulva fasciata and Taonia atomaria, showed high inhibition against E. coli and B.
subtilis [74]. In this work, SQDG was isolated from microalgae (S. brasiliensis ACOI 1261)
and cyanobacteria (Sphaerospermopsis sp. LEGE 00249) extracts (Table 1), with both cases
showing antibiotic activity against S. aureus.
Although the antimicrobial activities of lipids have been previously reported in several
microorganisms, with MICs above 100 µg/mL [13,20], recent studies suggest that lipids
exhibit antibiofilm activity against bacteria and fungi at lower concentrations than their cor-
responding MIC [17,75]. In our case, a lysophosphatidylcholine (C16:0 LPC) but not fatty
acids showed antibiofilm activity against K. pneumoniae, E. coli, S. epidermidis, and C. parap-
silosis. The effect of C16:0 LPC on Candida biofilms has also been studied previously [76],
attributing this inhibition activity to the induction of the reactive oxygen species system.
The authors found 54% of biofilm inhibition at a concentration of 500 mg/L, whereas
an inhibition of about 40–70% at concentrations ≤64 mg/L was observed in the present
work. C16:0 LPC has also been isolated from the methanolic extract of the cyanobacteria
Oscillatoria subuliformis [77]. This extract showed a biofilm inhibition activity of 56%. This
activity was maintained when the extract was used for coating catheters. The antibiofilm
activity of C16:0 LPC was also studied against Acinetobacter baumannii [67]. In this case, a
38% of biofilm formation inhibition was observed at a concentration of 0.02 mg/mL. This
activity was attributed to the decreased expression of the abaR gene in the presence of C16:0
LPC, decreasing N-acyl-homoserine lactone production and, thereby, interfering with the
QS system. In our case, C16:0 LPC alone was able to inhibit biofilm formation by up to 50%
at concentrations between 32 and 120 mg/L depending on the species analyzed.
ALA is the precursor of other important polyunsaturated fatty acids, such as eicos-
apentaenoic acid (EPA) and docosahexaenoic acid (DHA), all of which are considered as
high value products. The ALA produced by Scenedesmus strains showed antibiofilm activity.
Pure commercial ALA presented biofilm inhibition activity against P. aeruginosa, S. aureus,
and C. albicans at concentrations ≤ 64 mg/L, with this activity being remarkable in the
case of C. albicans with an MBIC of 1 mg/L. Other studies have evaluated the antibiofilm
activity of ALA isolated from animals and plants. ALA from a Scolopendra species showed
antibiofilm activity against C. albicans at a concentration of 20 mg/L [78]. In addition, ALA
isolated from the n-hexane extract of a semi-green plant showed antibiofilm activity against
Streptococcus mutants [79]. The antibiofilm effect of ALA in combination with antibiotics has
been tested by Chanda et al. (2017) [80]. They observed antibiofilm activity against P. aerug-
inosa combined with tobramycin mainly due to the ability of ALA to increase the bacterial
membrane fluidity, disrupting membrane permeability and enhancing the transport of
tobramycin into biofilm cells. In our case, ALA had an inhibitory effect on P. aeruginosa
biofilm formation being enhanced by the presence of C16:0 LPC. As C16:0 LPC and ALA
were elucidated in the composition of several active extracts of this study, the synergistic
effect of both as antibiofilm agents was studied. We observed that the effect is specific in
each studied species. Thus, K. pneumoniae, E. coli, S. epidermidis, and C. parapsilopsis were
more susceptible to the C16:0 LPC. On the other hand, C. albicans is affected only when
ALA is present in the culture media. P. aeruginosa showed biofilm inhibition in the presence
of ALA, alone or in combination with C16:0 LPC.
Another example highlighting the importance of lipids as antibiotic and antibiofilm
compounds is saw palmetto oil (Serenoa repens), composed of more than 90% fatty acids,
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including lauric acid, myristic acid, palmitic acid, and oleic acid. These oils are able to
inhibit biofilm formation by S. aureus, E. coli O157:H7, and C. albicans without affecting
their fitness. Transcriptomic analyses showed that lauric and myristic acids repressed the
expression of several biofilm-related genes (csgAB, fimH, and flhD) in E. coli and hypha cell
wall gene HWP1 in C. albicans. In addition, the combined treatment of both fatty acids at a
concentration of 20 µg/mL with gentamicin showed a synergistic antibacterial activity on
S. aureus and E. coli [81].
4. Materials and Methods
4.1. Microalgae and Cyanobacteria Strains
Freshwater strains Scenedesmus brasiliensis ACOI 1261, ACOI 565, and Enallax acuti-
formis ACOI 118 were obtained from the Coimbra Collection of Algae (http://acoi.ci.uc.pt).
Cultures were grown up to 56 L in multiple 10 L flasks (1:1 v/v) containing 4 L of M7
medium for 15 days with aeration at 25 ◦C under a light/dark cycle of 16:8 h and photon
irradiation of approximately 50 µmol m−2 s−1 for biomass extraction and subsequent
isolation of compounds. Cultures were harvested after reaching the stationary phase by
centrifugation (Thermo Scientific Megafuge 8, 4500 rpm, 15 min) and then freeze-dried.
The lyophilized biomass (~10 g) was disrupted using a ceramic mortar previously exposed
to liquid nitrogen followed by a sequential extraction with hexane, ethyl acetate, and
methanol. Extraction was performed by adding 4 × 500 mL of each solvent, followed
by vortex and centrifugation at 4500 rpm for 15 min. The supernatant was collected,
transferred to glass vials, and dried completely in a rotary evaporator (Table 5). The ex-
tracts were stored under cold, dark conditions until analysis to avoid hydrolysis of the
bioactive molecules.






ACOI 1261 136 69 1109
ACOI 118 301 214 821
ACOI 565 292 143 1316
The cyanobacterium strain Sphaerospermopsis sp. LEGE 00249 was obtained from LEGE
CC [27] (accession number: KC989701, 16S rRNA gene). The strain was cultured up to
50 L in Z8 medium [28] at 25 ◦C with constant aeration with a photoperiod of 14 h/10
h light and dark, respectively, and at light intensity of 10–30 µmols photons m−2 s−1.
At the exponential phase, cells were harvested through centrifugation, then frozen and
freeze-dried. The biomass (7.7 g d.w.) was sequentially extracted with hexane, ethyl acetate,
and methanol (Table 6).









LEGE 00249 66.07 352.88 949.65
4.2. Microbial Strains
Antibiotic assays were performed against a Gram-positive bacteria(Staphylococcus
aureus S54F9, spa type t1333) [82], a Gram-negative bacteria (Escherichia coli AR, collected
from urine at the Hospital Clinic of Barcelona), and a fungus (Candida parapsilosis SMI416,
non-biofilm-forming clinical isolate from a bloodstream infection) [83].
Biofilm inhibition of these extracts was assayed against Gram-negative strains of E. coli;
Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa; Gram-positivestrains
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of S. aureus, Coagulase-negative Streptococcus, and S. epidermidis; and C. albicans and C.
parapsilosis fungal strains.
4.3. Antibiotic Analysis
The three microbial pathogens (E. coli, S. aureus, and C. parapsilosis) were inoculated in
5 mL Mueller–Hinton broth (Oxoid) from glycerol stocks, incubated overnight at 37 ◦C with
agitation at 250 rpm, and diluted in Mueller–Hinton broth (MHB) up to the desired cell
density. The final concentration in the microtiter 96-well U-bottom plates (ThermoScientific)
was 5 × 105 colony-forming units (CFU)/mL for S. aureus and E. coli, and 2.5 × 105 CFU/mL
for C. parapsilosis.
When SPE-fractions and HPLC sub-fractions were tested for bioactivity-guided frac-
tionation purposes, no serial dilutions were performed (yes/no method). Briefly, 50 µL of
each SPE-fraction or sub-fraction resuspended in 14% MeOH in water (v/v) were mixed
with 50 µL of the microorganism suspension in a microtiter plate and incubated overnight
at 37 ◦C statically. Growth controls (broth with bacterial inoculum, without bioactive
molecules) as well as sterility (broth only) and solvent controls (bacterial inoculum with a
final concentration of 7% MeOH in water v/v) were also included.
When the antibiotic activity of ALA was studied, an MIC assay was carried out
following the guidelines of the Clinical and Laboratory Standards Institute (CLSI) [84].
A stock solution of ALA in 0.15 M aqueous solution of tris-HCl pH 8.5 was prepared and
serial two-fold dilutions ranging from 250 mg/mL to 0.244 mg/mL were carried out in a
microtiter plate with 50 µL of sterile Milli-Q water pre-added to all the wells. 50 µL of the
corresponding microorganism suspension in 2x MHB was added to all the wells. Growth,
sterility, and solvent controls were also included.
In all the cases, microbial sedimentation was checked by visual verification, and each
experiment was performed in duplicate. The minimum bactericidal/fungicidal concentra-
tion (MBC/MFC) was determined according to the CLSI protocol by plating 20 µL from
each well, showing no visible growth at 24 h, onto a solid medium. For that purpose,
the microtiter plate was replicated onto a selective/differential solid medium, such as
mannitol salt agar (MSA, VWR Chemicals) for S. aureus, eosin methylene blue (EMB, VWR
Chemicals) for E. coli, and Sabouraud agar (VWR Chemicals) for C. parapsilosis, with a
96-pin replicator in order to distinguish between bacteriostatic and bactericidal activities.
4.4. Antibiofilm Analysis
The antibiofilm assay was performed by the broth microdilution assay described in
the CLSI document M7-A7 [84] with some modifications described by Cepas et al. [8].
The results are expressed as percentage of biofilm inhibition observed in comparison
with the biofilm of the bacterial strain without extract. No MBIC values could be obtained
because the concentration of each compound in each fraction was not known.
The MBICs of both ALA and 1-Palmitoyl-sn-glycero-3-phosphocholine (C16:0 LPC)
were tested by serial dilutions from a concentration of 128 mg/L to 0.25 mg/L against
nine strains representing Gram-negative, Gram-positive, and fungi species (K. pneumoniae,
E. coli, P. aeruginosa, Enterobacter cloacae, S. aureus, Coagulase Negative Streptococcus, S.
epidermidis, C. parapsilosis, and C. albicans). Synergies between the two compounds were
also studied by the determination of the MBIC using mixtures of different proportions of
both compounds (1:0, 1:1, 1:0.5, 0.5:1, 0:1).
4.5. Solid Phase Extraction Methods for Methanolic and Ethyl Acetate Extracts
All the methanolic extracts (fraction code C) from microalgae strains (ACOI 565,
ACOI 118) were submitted to several non-retentive solid phase extractions (Phenomenex
Strata® C18-E, 55 µm, 10 g, 60 mL, C18 Cartridges) and developed ad hoc to reduce the
complexity of the samples as well as to eliminate column killers that could compromise
further purification steps. Hence, the analytes of interest were eluted, and the interferences
were retained in the sorbent. A maximum of 10 mL of the microalgae extracts sample
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reconstituted in MeOH 20% (v/v) was added to the conditioned sorbent and, for the
elution (4 to 8 bed volumes each), a gradient solvent of H2O (A) and MeOH (B) from 20 to
100% B in 10% steps (C1–C9) followed by a washing step with acetone (C10) was used.
All the SPE fractions were dried out under vacuum in a rotavapor (RV 10 Digital, IKA)
equipped with a vertical condenser maintained at −10 ◦C (RC-10 Digital Chiller, VWR).
The ethyl acetate extract (fraction code B) from the ACOI 1261 strain was submitted to
SPE (Sep-Pak® Waters® Silica, 55 µm, 5 g, 20 cc, vac cartridge). In this case, a maximum
of 5 mL of the microalgae extract reconstituted in EtOAc/Hex 20:80 (v/v) was added to
the conditioned stationary phase and 4-8 bed volumes were used for the stepwise elution,
which was performed as follows: from EtOAc/Hex 20:80 (v/v) to EtOAc 100% in 10%
steps (B1-B9) followed by a washing step with MeOH/EtOAc 25:75 (v/v) (B10). Each SPE
fraction was dried out as described previously.
4.6. Bioassay-Guided HPLC-DAD Purification
The active SPE fractions in antibiotic and/or antibiofilm tests were selected for further
purification and filtered through 0.8 and 0.2 µm filters (Acrodisc®, Pall, NY, USA). For
each fraction, a customized analytical HPLC program that assured the best peak resolution
in 30 min was designed, and an Agilent 1260 Inifinity LC system equipped with an
analytical reversed-phase RP-18 HPLC column (250 × 4.0 mm, Pursuit® XRs, 5 µm, Agilent
Technologies) was used for that purpose. The column was coupled to a UV detector set
to 255 and 280 nm at a flow rate of 1 mL/min, and 50 µg of sample was injected. The
corresponding analytical program was scaled up to semi-preparative conditions with the
Waters Gradient Calculator (Waters Corporation, Milford, MA, USA). At this purification
step, a semipreparative RP-18 HPLC column (250 × 10.0 mm, Pursuit XRs, 5 µm, (Agilent
Technologies, Santa Clara, CA, USA) with a guard column (50 × 10.0 mm, Pursuit® XRs,
5 µm, Agilent Technologies) was used. The flow rate was increased up to 4 mL/min over a
period of 47 minutes and sub-fractions were collected every 30 seconds (94 sub-fractions
in total, 2 mL per fraction) in a 96-well DeepWell plates (ThermoScientific, Waltham, MA,
USA). Wells 95 and 96 were empty to remain solvent and negative controls, respectively,
in antibiotic and antibiofilm assays. As a general rule, a maximum of 50 mg was used in
each semipreparative injection in order to avoid detector saturation; therefore, on many
occasions, several iterative rounds of purification were needed. Under both analytical and
semipreparative conditions, H2O (A) and MeCN (B) were used as mobile phases, both
with 0.1% (v/v) of formic acid.
The semipreparative programs for the different SPE fractions with antibiotic and/or
antibiofilm activity were as follows. For the ACOI565_C4 extract (27 mg): 0–3.13 min
(25% B), 3.13-37.5 min (25–100% B), 37.5–40.63 min (100% B), 40.63–42.19 min (100-25% B),
and 42.19–47 min (25% B); for the ACOI565_C8 extract (129.1 mg): 0–3.13 min (40% B),
3.13–31.25 min (40–100% B), 31.25–37.5 min (100% B), 37.5–39.06 min (100–40% B), and
39.06–47 min (40% B); for the ACOI1261_C8 extract (116.5 mg): 0–1 min (35% B), 1–3 min
(35–60% B), 3–9 min (60–85% B), 9–32 min (85–100% B), 32–40 min (100% B), 40–41 min
(100–35%), and 41–47 min (35% B); and for the ACOI118_C6 extract (9 mg): 0–3 min (60% B),
3–31 min (60–100% B), 31–40 min (100% B), 40–41 min (100–60% B), and 41–47 min (60% B).
In the case of the methanol extract of the cyanobacterium Sphaerospermopsis sp. LEGE00249,
an SPE was also performed, followed by a semi-preparative HPLC-DAD fractionation,
as described in [9]. Briefly, a first round of fractionation gave rise to three groups of
bioactivities, and the first group (group A, 14 mg) was pooled and subjected to a second
round of purification, obtaining 94 new sub-fractions. The complete list of isolated fractions
and sub-fractions amounts is described in Table 7.
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Table 7. SPE fractions and HPLC-DAD sub-fractions yields.
Microalgae/Cyanobacteria
Strain SPE-Fraction HPLC Sub-Fraction










C8 (129.1 mg) F67 (5.4 mg)
F48–49 (2.4 mg)





The HPLC active sub-fractions and inactive flanking sub-fractions were injected into
HPLC-HRESIMS equipment to decipher which m/z ions were responsible for the detected
bioactivity. For that purpose, a UPLC system (Dionex Ultimate 3000, ThermoScientific)
coupled to an ESI-UHR-Qq-TOF Impact II spectrometer (Bruker), which acquired data
in the negative or positive ion mode, with a m/z range from 40 to 2000 Da, was used.
For the chromatographic separation, elution was performed through an analytical RP-18
HPLC column (50 × 2.1 mm, Zorbax®Eclipse Plus, 1.8 µm, Agilent Technologies) with
a combination of H20 (A) and MeCN (B), both with 0.1% (v/v) of formic acid. Analytes
were eluted at a flow rate of 0.25 mL/min under the following conditions: 0–1 min (10% B),
1–4 min (10–35% B), 4–5 min (35% B), 5–8 min (35–100% B), 8–10 min (100% B), 1-11 min
(100–10% B), and 11–15 min (10% B). Data were analyzed using Compass DataAnalysis
4.3 (Bruker).
4.8. NMR Assays
All the 1H, 13C{1H}, 31P{1H}, and 2D NMR spectra were recorded on a Bruker Avance
III HD 600 MHz NMR (14.0 T) spectrometer equipped with a QCI-P CryoProbe™ (proton-
optimized quadruple resonance NMR ‘inverse’ probe). The samples were prepared by dis-
solving the microalgae and cyanobacteria extracts in 0.5 mL of methanol-d4. Key parameters
for the acquisition of 1D and 2D NMR spectra were the same as previously reported [57,85].
TopSpin 3.6 (Bruker) was used for acquiring and processing the NMR spectra.
4.9. Reagents and Biochemicals
All solvents used for SPE extraction, HPLC-DAD purification, and mass spectrometry
analysis were LC-MS grade from either Sigma-Aldrich or VWR Chemicals. Authentic ALA
was purchased from Cayman Chemical, and 1-palmitoyl-sn-glycero-3-phosphocholine
(C16:0 LPC) was purchased from Sigma-Aldrich.
5. Conclusions
Cyanobacteria and microalgae produce a great variety of lipids with antibiotic and
antibiofilm activity against the most important pathogens causing severe infections in
humans. Therefore, their use in clinical treatments alone or in combination with well-
known antibiotics requires further investigation as an alternative to the current treatments.
However, further studies are needed to determine the in vivo efficacy of these lipids, their
mechanisms of action, and their availability in the amounts required.
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